Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May;22(5):567-569.
doi: 10.1016/S1473-3099(21)00762-3. Epub 2021 Dec 23.

Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19

Adrienne E Shapiro  1 , Rachel A Bender Ignacio  2
Affiliations
Comment

Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19

Adrienne E Shapiro et al. Lancet Infect Dis. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

AES has received grant funding through her institution from Vir Biotechnology, as an investigator to conduct the COMET-ICE and COMET-TAIL clinical trials of Vir-7831 in non-hospitalised patients with COVID-19. RABI has received grant funding from the US National Institutes of Health through her institution to conduct COVID-19 therapeutic trials in outpatients as an investigator in the ACTIV2 platform.

Figures

Figure
Figure
Role for anti-SARS-CoV-2 antibodies in the disease course of COVID-19 As disease states progress from preinfection through to critical illness (blue boxes), the potential for antibodies to mitigate illness decreases (dark blue arrow) as pathology transitions from being virally mediated, where antiviral acting therapies are most effective (green triangle), to a hyper-inflammatory state best treated with immunomodulatory therapies (orange triangle).
See this image and copyright information in PMC

Comment on

References

    1. Normand ST. The RECOVERY platform. N Engl J Med. 2021;384:757–758. - PMC - PubMed
    1. National Institutes of Health Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV) 2021. https://www.nih.gov/research-training/medical-research-initiatives/activ
    1. Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for COVID-19—interim WHO Solidarity trial results. N Engl J Med. 2021;384:497–511. - PMC - PubMed
    1. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N Engl J Med. 2021;384:238–251. - PMC - PubMed
    1. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941–1950. - PubMed

Substances